Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 17Thoracic 2Gastrointestinal 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 786Lung Neoplasms 347Small Cell Lung Carcinoma 146Adenocarcinoma of Lung 71Neoplasms 45Neoplasm Metastasis 35Adenocarcinoma, Bronchiolo-Alveolar 30Colorectal Neoplasms 26Carcinoma 25Ovarian Neoplasms 24Lung Diseases 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Breast Neoplasms 17Mesothelioma 16Thoracic Neoplasms 15Respiratory Tract Neoplasms 15Mesothelioma, Malignant 15Pancreatic Neoplasms 14NSCLC 13Endometrial Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Bronchogenic 12Adenocarcinoma 12Melanoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Brain Neoplasms 10Respiratory Tract Diseases 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9

Interventions

Cisplatin 4Fluorouracil 3Oxaliplatin 2Leucovorin 2Hyperthermic Intraperitoneal Chemotherapy 2Cytoreduction Surgical Procedures 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1pembrolizumab 1durvalumab 1cc-486 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Mitomycin 1Ifosfamide 1Gemcitabine 1EC regimen 1Doxorubicin 1CP protocol 1Azacitidine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Carboplatin × Thoracic × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡